BioNTech Slips Below €79 as BNT113 Trial Misses First Hurdle
Published on 10/17/2026 at 05:50 | Editorial boerse-global.de
BioNTech shares are nursing a double-digit weekly deficit, and the trigger is clinical rather than commercial. The Mainz-based group's stock has come under sustained pressure since its AHEAD-MERIT study — testing the combination of BNT113 and pembrolizumab against pembrolizumab alone — failed to deliver a statistically significant improvement in progression-free survival, missing the first of its dual primary endpoints.
The stock closed Friday down 3.0% at €78.05, extending a seven-day decline of 9.1%. That leaves the shares 26% below their 52-week high, a stark marker of how far the vaccine-era euphoria has cooled.
A Trial That Continues, a Question That Remains
The independent monitoring committee did not pull the plug. It recommended that AHEAD-MERIT carry on so that overall survival data can be assessed — and that readout now carries outsized weight. Canaccord Genuity made the same point on October 14, when it trimmed its price target to $132 from $136 while keeping a "Buy" rating. The analysts tied the cut directly to the BNT113 progression-free survival results, noting that the overall survival assessment in the ongoing trial is still pending.
The distinction matters. Markets had treated the study as a key gauge of whether mRNA technology can be transferred to solid tumours, and the miss on the first endpoint has forced a rethink of how much of that promise should be priced in today.
Should investors sell immediately? Or is it worth buying BioNTech?
Sector Sympathy, Not Contagion
The weakness was not BioNTech's alone. Moderna shares came under noticeable selling pressure after a prior rally, with media reports pointing to profit-taking across the mRNA cancer-therapy space. BioNTech declined alongside its peer, though its losses were the more moderate of the two on the day. Market observers drew no causal link between Moderna's move and BioNTech's slide — but the shared direction underlined how twitchy sentiment has become around any news from mRNA oncology.
Insider Sales Add a Psychological Layer
Filings with the US Securities and Exchange Commission also drew attention to transactions by CEO U?ur ?ahin, disclosing sales of 36,209 ordinary shares executed under a pre-arranged Rule 10b5-1 trading plan. Such plans are designed to fix executive sales in advance on set parameters, so trades run independently of day-to-day events — standard practice on US markets. In an already jittery environment, though, the disclosure did not pass unnoticed.
From Pandemic Hero to Oncology Hopeful
For shareholders, the shift from vaccine darling to diversified cancer therapeutics company is proving a test of patience above all. The AHEAD-MERIT data counsel sobriety: in oncology, only robust evidence of efficacy counts, and setbacks are part of pharmaceutical development reality. Clinical trials rarely run in straight lines, and market participants are no longer paying for partial successes in advance.
Until landmark study wins arrive, disappointments like BNT113 look set to weigh on the valuation again and again. The next inflection point is clear — further overall survival data from AHEAD-MERIT will determine how the prospects for BNT113 are judged from here.
Ad
BioNTech Stock: New Analysis - 17 October
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
